MYGN logo

Myriad Genetics (MYGN) Accounts Receivable

Annual Accounts Receivable

$114.30 M
+$12.70 M+12.50%

December 1, 2023

Summary

Performance

1-Year Change

+12.5%

3-Year Change

+27.71%

5-Year Change

-14.64%

15-Year Change

+26.72%

MYGN Accounts Receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

75.86%
MYGN annual accounts receivable is higher than 75.86% of companies in Healthcare sector

High & Low

All-time High

$133.90 M
MYGN annual accounts receivable is currently -14.64% below its historical high of $133.90 million

3-Year Low

$91.30 M
MYGN annual accounts receivable is currently +25.19% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2023
MYGN previous annual earnings announcement was published on Dec 1, 2023

Next Annual Earnings Report Date

Feb 27, 2025
MYGN next annual earnings announcement is scheduled for Feb 27, 2025

OtherMYGNbalance sheetmetrics:

Annual Accounts Payable

$25.80 M
MYGN annual accounts payable is $25.80 million

Annual Total Assets

$1.15 B
MYGN annual total assets is $1.15 billion

Annual Total Liabilities

$363.30 M
MYGN annual total liabilities is $363.30 million

Annual Cash & Cash Equivalents

$132.10 M
MYGN annual cash & cash equivalents is $132.10 million

Quarterly Accounts Receivable

$125.70 M
+$7.90 M+6.71%

September 1, 2024

Summary

Performance

3-Month Change

+6.71%

1-Year Change

+6.44%

3-Year Change

+23.72%

5-Year Change

+6.26%

MYGN Quarterly Accounts Receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

77.16%
MYGN quarterly accounts receivable is higher than 77.16% of companies in Healthcare sector

High & Low

All-time High

$142.60 M
MYGN quarterly accounts receivable is currently -11.85% below its historical high of $142.60 million

3-Year Low

$91.30 M
MYGN quarterly accounts receivable is currently +37.68% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
MYGN previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

Feb 27, 2025
MYGN next earnings announcement is scheduled for Feb 27, 2025

OtherMYGNbalance sheetmetrics:

Quarterly Accounts Payable

$29.60 M
MYGN quarterly accounts payable is $29.60 million

Quarterly Total Assets

$1.08 B
MYGN quarterly total assets is $1.08 billion

Quarterly Total Liabilities

$349.60 M
MYGN quarterly total liabilities is $349.60 million

Quarterly Cash And Cash Equivalents

$99.90 M
MYGN quarterly cash and cash equivalents is $99.90 million

Accounts Receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

MYGN Accounts Receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+12.5%+6.4%
3 y3 years+27.7%+23.7%
5 y5 years-14.6%+6.3%

MYGN Accounts Receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+25.2%at high+37.7%
5 y5-year-14.6%+67.8%at high+84.6%
alltimeall time-14.6%+3471.9%-11.8%+5494.1%

Myriad Genetics Accounts Receivable History

DateAnnualQuarterly
Sep 2024
-
$125.70 M(+6.7%)
Jun 2024
-
$117.80 M(-0.3%)
Mar 2024
-
$118.10 M(+3.3%)
Dec 2023
$114.30 M(+12.5%)
$114.30 M(-0.8%)
Sep 2023
-
$115.20 M(+3.1%)
Jun 2023
-
$111.70 M(-6.2%)
Mar 2023
-
$119.10 M(+17.2%)
Dec 2022
$101.60 M(+11.3%)
$101.60 M(-0.6%)
Sep 2022
-
$102.20 M(-6.9%)
Jun 2022
-
$109.80 M(+8.0%)
Mar 2022
-
$101.70 M(+11.4%)
Dec 2021
$91.30 M(+2.0%)
$91.30 M(-2.5%)
Sep 2021
-
$93.60 M(-1.3%)
Jun 2021
-
$94.80 M(+0.7%)
Mar 2021
-
$94.10 M(+10.6%)
Dec 2020
$89.50 M(+31.4%)
-
Sep 2020
-
$85.10 M(+25.0%)
Jun 2020
$68.10 M(-49.1%)
$68.10 M(-33.6%)
Mar 2020
-
$102.50 M(-13.4%)
Dec 2019
-
$118.30 M(+1.1%)
Sep 2019
-
$117.00 M(-12.6%)
Jun 2019
$133.90 M(+34.6%)
$133.90 M(-6.1%)
Mar 2019
-
$142.60 M(+22.3%)
Dec 2018
-
$116.60 M(-2.1%)
Sep 2018
-
$119.10 M(+19.7%)
Jun 2018
$99.50 M(+10.3%)
$99.50 M(-19.6%)
Mar 2018
-
$123.70 M(+2.1%)
Dec 2017
-
$121.10 M(+7.0%)
Sep 2017
-
$113.20 M(+25.5%)
Jun 2017
$90.20 M(-1.6%)
$90.20 M(-21.4%)
Mar 2017
-
$114.80 M(+6.7%)
Dec 2016
-
$107.60 M(+9.6%)
Sep 2016
-
$98.20 M(+7.1%)
Jun 2016
$91.70 M(+6.9%)
$91.70 M(+0.7%)
Mar 2016
-
$91.10 M(+8.1%)
Dec 2015
-
$84.30 M(+1.1%)
Sep 2015
-
$83.40 M(-2.8%)
Jun 2015
$85.80 M(+4.8%)
$85.80 M(-6.9%)
Mar 2015
-
$92.19 M(+13.5%)
Dec 2014
-
$81.22 M(+7.3%)
Sep 2014
-
$75.72 M(-7.5%)
Jun 2014
$81.90 M(-13.2%)
$81.90 M(-0.9%)
Mar 2014
-
$82.68 M(-1.7%)
Dec 2013
-
$84.14 M(-2.4%)
Sep 2013
-
$86.22 M(-8.6%)
Jun 2013
$94.33 M(+56.1%)
$94.33 M(+1.2%)
Mar 2013
-
$93.17 M(+23.3%)
Dec 2012
-
$75.56 M(+20.9%)
Sep 2012
-
$62.50 M(+3.4%)
DateAnnualQuarterly
Jun 2012
$60.44 M(+20.2%)
$60.44 M(+18.6%)
Mar 2012
-
$50.95 M(+18.5%)
Dec 2011
-
$42.99 M(-4.1%)
Sep 2011
-
$44.82 M(-10.8%)
Jun 2011
$50.27 M(+5.2%)
$50.27 M(+8.3%)
Mar 2011
-
$46.44 M(+15.9%)
Dec 2010
-
$40.06 M(-8.6%)
Sep 2010
-
$43.83 M(-8.3%)
Jun 2010
$47.80 M(+7.1%)
$47.80 M(-0.7%)
Mar 2010
-
$48.12 M(-1.3%)
Dec 2009
-
$48.77 M(+11.5%)
Sep 2009
-
$43.74 M(-2.0%)
Jun 2009
$44.62 M(+9.7%)
$44.62 M(-6.0%)
Mar 2009
-
$47.47 M(+14.6%)
Dec 2008
-
$41.43 M(-11.7%)
Sep 2008
-
$46.93 M(+15.4%)
Jun 2008
$40.66 M(+30.7%)
$40.66 M(+2.4%)
Mar 2008
-
$39.70 M(+3.2%)
Dec 2007
-
$38.47 M(+14.9%)
Sep 2007
-
$33.49 M(+7.7%)
Jun 2007
$31.10 M(+49.4%)
$31.10 M(+22.2%)
Mar 2007
-
$25.46 M(+6.1%)
Dec 2006
-
$24.01 M(+3.6%)
Sep 2006
-
$23.16 M(+11.2%)
Jun 2006
$20.82 M(+20.8%)
$20.82 M(+1.5%)
Mar 2006
-
$20.51 M(+8.1%)
Dec 2005
-
$18.98 M(+1.2%)
Sep 2005
-
$18.75 M(+8.8%)
Jun 2005
$17.24 M(+23.2%)
$17.24 M(+6.6%)
Mar 2005
-
$16.17 M(-6.4%)
Dec 2004
-
$17.28 M(+3.9%)
Sep 2004
-
$16.63 M(+18.8%)
Jun 2004
$13.99 M(+8.3%)
$13.99 M(-5.5%)
Mar 2004
-
$14.82 M(+12.3%)
Dec 2003
-
$13.19 M(+6.6%)
Sep 2003
-
$12.37 M(-4.2%)
Jun 2003
$12.92 M(+78.6%)
$12.92 M(+10.3%)
Mar 2003
-
$11.71 M(+25.3%)
Dec 2002
-
$9.34 M(+7.3%)
Sep 2002
-
$8.70 M(+20.3%)
Jun 2002
$7.23 M(+99.0%)
$7.23 M(+1.1%)
Mar 2002
-
$7.15 M(+44.0%)
Dec 2001
-
$4.97 M(+34.9%)
Sep 2001
-
$3.68 M(+1.3%)
Jun 2001
$3.63 M(+13.6%)
$3.63 M(+3.7%)
Mar 2001
-
$3.51 M(-6.9%)
Dec 2000
-
$3.77 M(+15.4%)
Sep 2000
-
$3.26 M(+45.2%)
Mar 2000
-
$2.25 M(-29.8%)
Jun 1999
$3.20 M
$3.20 M

FAQ

  • What is Myriad Genetics annual accounts receivable?
  • What is the all time high annual accounts receivable for Myriad Genetics?
  • What is Myriad Genetics annual accounts receivable year-on-year change?
  • What is Myriad Genetics quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Myriad Genetics?
  • What is Myriad Genetics quarterly accounts receivable year-on-year change?

What is Myriad Genetics annual accounts receivable?

The current annual accounts receivable of MYGN is $114.30 M

What is the all time high annual accounts receivable for Myriad Genetics?

Myriad Genetics all-time high annual accounts receivable is $133.90 M

What is Myriad Genetics annual accounts receivable year-on-year change?

Over the past year, MYGN annual accounts receivable has changed by +$12.70 M (+12.50%)

What is Myriad Genetics quarterly accounts receivable?

The current quarterly accounts receivable of MYGN is $125.70 M

What is the all time high quarterly accounts receivable for Myriad Genetics?

Myriad Genetics all-time high quarterly accounts receivable is $142.60 M

What is Myriad Genetics quarterly accounts receivable year-on-year change?

Over the past year, MYGN quarterly accounts receivable has changed by +$7.60 M (+6.44%)